China-Australia Biomedical Innovation Initiative
2025-11-13 19:27:20

China-Australia Biomedical Innovation Initiative

Jointly launched with the China-Australia Innovation Cooperation Center for Emerging Industries, the "China-Australia Biomedical Innovation Initiative" has invested 15 million yuan in R&D funds. It has collaborated with enterprises including Australia’s CSL Limited and China’s Fosun Pharma to tackle key technologies of "novel vaccine adjuvant technology". Currently, preclinical research has been completed, and the initiative is expected to enter the clinical trial phase in 2028, which will fill the gap in relevant technologies in the Asia-Pacific region.